期刊
TETRAHEDRON LETTERS
卷 88, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.tetlet.2021.153590
关键词
Remdesivir; Nucleotide; Nucleoside; COVID-19; RdRp
资金
- University Grants Commission (UGC), New Delhi
- CSIR, New Delhi
- Science and Engineering Research Board (SERB), Government of India [SB/S2/JCB-002/2015]
- Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India [HCP 0029]
Remdesivir, the first drug approved by the FDA to treat COVID-19, is highly demanded for patients infected with the SARS-CoV-2 virus. A facile approach minimizing protecting group manipulations to afford remdesivir in good overall yield is reported in this study.
Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield. (c) 2021 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
